_id
6915fdb0bc934aba376b2818
Ticker
SPRBD
Name
Spruce Biosciences, Inc.
Exchange
OTCQB
Address
611 Gateway Boulevard, South San Francisco, CA, United States, 94080
Country
USA
Sector
Healthcare
Industry
Biotechnology
Currency
USD
Website
https://sprucebio.com
Description
Spruce Biosciences, Inc. is a biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders. The company develops TA-ERT, a fusion protein comprised of recombinant human alpha-N-acetylglucosaminidase, which is an enzyme replacement therapy for patients with Sanfilippo Syndrome Type B. It also develops Tildacerfont for treating a highly debilitating mental disorder characterized by depressed mood with cognitive-affective and somatic changes, including anhedonia, weight alterations, and altered sleeping patterns. In addition, the company develops SPR202 for the treatment of Congenital Adrenal Hyperplasia (CAH), a chronic and potentially life-threatening rare disease with no cure, and SPR204, a monoclonal antibody antagonist for Post-Bariatric Hypoglycemia. The company has a license agreement with Eli Lilly and Company to research, develop, and commercialize various pharmaceutical compounds. It also has a collaboration and license agreement with Kaken Pharmaceutical Co. Ltd. to develop, manufacture, and commercialize Tildacerfont for the treatment of CAH in Japan. Spruce Biosciences, Inc. was incorporated in 2014 and is headquartered in South San Francisco, California.
Last Close
101.1
Volume
305222
Current Price
105
Change
2.39
Last Updated
2025-11-24T11:54:08.287Z
Image
data:image/webp;base64,UklGRsoAAABXRUJQVlA4IL4AAABQCACdASpAAEAAPrVMnkmnJKKhMfqoAOAWiWcA0nBFlGy2hu+YZQP+QCMrwBa0aj+H3qLpVksl2cR8XWTcsC5TxRttc/8Lmqnj0gAA/veMAAGUMklcWwf7diMIj/r8NAqkBC4OlWUle3r1yhnkL3rjWBUeel7lvMDyzTYrg1tsOieQTCd/mlQBFgxyMrPVIfR4j96vQ2Hsb2wFDOjntmRb7eI8rTeR6S8HfzDcro0ZYE78C57oT2tOOtGMhgAA
Ipo Date
-
Market Cap
-
Next Dividend Date
-
Dividend Frequency
-
Dividend Rate
-
Dividend Yield
0
Sentiment
-
Sentiment Sources
0
Current Quarter
2025-09-30
Revenue
0
Cost Of Revenue
-
Gross Profit
-
Operating Expenses
8229000
Operating Income
-8229000
Interest Expense
19000
Pretax Income
-8212000
Net Income
-8212000
Eps
-14.573435955498846
Dividends Per Share
-
Shares Outstanding
563491
Income Tax Expense
-
EBITDA
-
Operating Margin
-
Total Other Income Expense Net
-
Cash
10669000
Short Term Investments
-
Receivables
-
Inventories
-
Total Current Assets
14516000
Property Plant Equipment
735000
Total Assets
15313000
Payables
1386000
Short Term Debt
-
Long Term Debt
-
Total Liabilities
9927000
Equity
5386000
Depreciation
3000
Change In Working Capital
2308000
Cash From Operations
-5316000
Capital Expenditures
0
Cash From Investing
-
Cash From Financing
-402000
Net Change In Cash
-5718000
PE
-
PB
10.985249721500187
ROE
-152.4693650204233
ROA
-53.62763664859923
FCF
-5316000
Fcf Percent
-
Piotroski FScore
1
Health Score
25
Deep Value Investing Score
1
Defensive Investing Score
5.5
Dividend Investing Score
1.5
Economic Moat Investing Score
2.8
Garp Investing Score
1
Growth Investing Score
0.5
Momentum Investing Score
2.5
Net Net Investing Score
2
Quality Investing Score
1.5
Value Investing Score
3.5
Quarters > 0 > quarter
2025-09-30
Quarters > 0 > income Statement > revenue
0
Quarters > 0 > income Statement > cost Of Revenue
-
Quarters > 0 > income Statement > gross Profit
-
Quarters > 0 > income Statement > operating Expenses
8229000
Quarters > 0 > income Statement > operating Income
-8229000
Quarters > 0 > income Statement > interest Expense
19000
Quarters > 0 > income Statement > pretax Income
-8212000
Quarters > 0 > income Statement > net Income
-8212000
Quarters > 0 > income Statement > eps
-14.573435955498846
Quarters > 0 > income Statement > dividends Per Share
-
Quarters > 0 > income Statement > shares Outstanding
563491
Quarters > 0 > income Statement > income Tax Expense
-
Quarters > 0 > income Statement > EBITDA
-
Quarters > 0 > income Statement > operating Margin
-
Quarters > 0 > income Statement > total Other Income Expense Net
-
Quarters > 0 > balance Sheet > cash
10669000
Quarters > 0 > balance Sheet > short Term Investments
-
Quarters > 0 > balance Sheet > receivables
-
Quarters > 0 > balance Sheet > inventories
-
Quarters > 0 > balance Sheet > total Current Assets
14516000
Quarters > 0 > balance Sheet > property Plant Equipment
735000
Quarters > 0 > balance Sheet > total Assets
15313000
Quarters > 0 > balance Sheet > payables
1386000
Quarters > 0 > balance Sheet > short Term Debt
-
Quarters > 0 > balance Sheet > long Term Debt
-
Quarters > 0 > balance Sheet > total Liabilities
9927000
Quarters > 0 > balance Sheet > equity
5386000
Quarters > 0 > cash Flow > net Income
-8212000
Quarters > 0 > cash Flow > depreciation
3000
Quarters > 0 > cash Flow > change In Working Capital
2308000
Quarters > 0 > cash Flow > cash From Operations
-5316000
Quarters > 0 > cash Flow > capital Expenditures
0
Quarters > 0 > cash Flow > cash From Investing
-
Quarters > 0 > cash Flow > cash From Financing
-402000
Quarters > 0 > cash Flow > net Change In Cash
-5718000
Quarters > 0 > ratios > PE
-14.573435955498846
Quarters > 0 > ratios > PB
10.985249721500187
Quarters > 0 > ratios > ROE
-152.4693650204233
Quarters > 0 > ratios > ROA
-53.62763664859923
Quarters > 0 > ratios > FCF
-5316000
Quarters > 0 > ratios > Piotroski FScore
1
Quarters > 0 > ratios > fcf Percent
-
Quarters > 0 > health Score
25
Quarters > 1 > quarter
2025-06-30
Quarters > 1 > income Statement > revenue
0
Quarters > 1 > income Statement > cost Of Revenue
-
Quarters > 1 > income Statement > gross Profit
-
Quarters > 1 > income Statement > operating Expenses
2692000
Quarters > 1 > income Statement > operating Income
-2692000
Quarters > 1 > income Statement > interest Expense
29000
Quarters > 1 > income Statement > pretax Income
-2067000
Quarters > 1 > income Statement > net Income
-2067000
Quarters > 1 > income Statement > eps
-3.671135849787138
Quarters > 1 > income Statement > dividends Per Share
-
Quarters > 1 > income Statement > shares Outstanding
563041
Quarters > 1 > income Statement > income Tax Expense
-
Quarters > 1 > income Statement > EBITDA
-
Quarters > 1 > income Statement > operating Margin
-
Quarters > 1 > income Statement > total Other Income Expense Net
-
Quarters > 1 > balance Sheet > cash
16387000
Quarters > 1 > balance Sheet > short Term Investments
-
Quarters > 1 > balance Sheet > receivables
-
Quarters > 1 > balance Sheet > inventories
-
Quarters > 1 > balance Sheet > total Current Assets
20953000
Quarters > 1 > balance Sheet > property Plant Equipment
803000
Quarters > 1 > balance Sheet > total Assets
21820000
Quarters > 1 > balance Sheet > payables
807000
Quarters > 1 > balance Sheet > short Term Debt
-
Quarters > 1 > balance Sheet > long Term Debt
-
Quarters > 1 > balance Sheet > total Liabilities
8640000
Quarters > 1 > balance Sheet > equity
13180000
Quarters > 1 > cash Flow > net Income
-2067000
Quarters > 1 > cash Flow > depreciation
7000
Quarters > 1 > cash Flow > change In Working Capital
-6296000
Quarters > 1 > cash Flow > cash From Operations
-8828000
Quarters > 1 > cash Flow > capital Expenditures
0
Quarters > 1 > cash Flow > cash From Investing
-
Quarters > 1 > cash Flow > cash From Financing
-400000
Quarters > 1 > cash Flow > net Change In Cash
-9228000
Quarters > 1 > ratios > PE
-3.671135849787138
Quarters > 1 > ratios > PB
4.485531487101669
Quarters > 1 > ratios > ROE
-15.682852807283762
Quarters > 1 > ratios > ROA
-9.472960586617782
Quarters > 1 > ratios > FCF
-8828000
Quarters > 1 > ratios > Piotroski FScore
0
Quarters > 1 > ratios > fcf Percent
-
Quarters > 1 > health Score
33
Quarters > 2 > quarter
2025-03-31
Quarters > 2 > income Statement > revenue
0
Quarters > 2 > income Statement > cost Of Revenue
-
Quarters > 2 > income Statement > gross Profit
-
Quarters > 2 > income Statement > operating Expenses
14492000
Quarters > 2 > income Statement > operating Income
-14492000
Quarters > 2 > income Statement > interest Expense
36000
Quarters > 2 > income Statement > pretax Income
-14041000
Quarters > 2 > income Statement > net Income
-14041000
Quarters > 2 > income Statement > eps
-24.935933068481912
Quarters > 2 > income Statement > dividends Per Share
-
Quarters > 2 > income Statement > shares Outstanding
563083
Quarters > 2 > income Statement > income Tax Expense
-
Quarters > 2 > income Statement > EBITDA
-
Quarters > 2 > income Statement > operating Margin
-
Quarters > 2 > income Statement > total Other Income Expense Net
-
Quarters > 2 > balance Sheet > cash
25615000
Quarters > 2 > balance Sheet > short Term Investments
-
Quarters > 2 > balance Sheet > receivables
-
Quarters > 2 > balance Sheet > inventories
-
Quarters > 2 > balance Sheet > total Current Assets
30576000
Quarters > 2 > balance Sheet > property Plant Equipment
869000
Quarters > 2 > balance Sheet > total Assets
31649000
Quarters > 2 > balance Sheet > payables
1879000
Quarters > 2 > balance Sheet > short Term Debt
-
Quarters > 2 > balance Sheet > long Term Debt
-
Quarters > 2 > balance Sheet > total Liabilities
16325000
Quarters > 2 > balance Sheet > equity
15324000
Quarters > 2 > cash Flow > net Income
-14041000
Quarters > 2 > cash Flow > depreciation
6000
Quarters > 2 > cash Flow > change In Working Capital
857000
Quarters > 2 > cash Flow > cash From Operations
-12727000
Quarters > 2 > cash Flow > capital Expenditures
0
Quarters > 2 > cash Flow > cash From Investing
-
Quarters > 2 > cash Flow > cash From Financing
-411000
Quarters > 2 > cash Flow > net Change In Cash
-13138000
Quarters > 2 > ratios > PE
-24.935933068481912
Quarters > 2 > ratios > PB
3.8582429522317936
Quarters > 2 > ratios > ROE
-91.62751239885148
Quarters > 2 > ratios > ROA
-44.36475086100667
Quarters > 2 > ratios > FCF
-12727000
Quarters > 2 > ratios > Piotroski FScore
1
Quarters > 2 > ratios > fcf Percent
-
Quarters > 2 > health Score
28
Quarters > 3 > quarter
2024-12-31
Quarters > 3 > income Statement > revenue
697000
Quarters > 3 > income Statement > cost Of Revenue
-
Quarters > 3 > income Statement > gross Profit
-
Quarters > 3 > income Statement > operating Expenses
24771000
Quarters > 3 > income Statement > operating Income
-24074000
Quarters > 3 > income Statement > interest Expense
56000
Quarters > 3 > income Statement > pretax Income
-23559000
Quarters > 3 > income Statement > net Income
-23559000
Quarters > 3 > income Statement > eps
-41.839302553975166
Quarters > 3 > income Statement > dividends Per Share
-
Quarters > 3 > income Statement > shares Outstanding
563083
Quarters > 3 > income Statement > income Tax Expense
-
Quarters > 3 > income Statement > EBITDA
-
Quarters > 3 > income Statement > operating Margin
-3453.945480631277
Quarters > 3 > income Statement > total Other Income Expense Net
-
Quarters > 3 > balance Sheet > cash
38753000
Quarters > 3 > balance Sheet > short Term Investments
-
Quarters > 3 > balance Sheet > receivables
-
Quarters > 3 > balance Sheet > inventories
-
Quarters > 3 > balance Sheet > total Current Assets
44206000
Quarters > 3 > balance Sheet > property Plant Equipment
934000
Quarters > 3 > balance Sheet > total Assets
45209000
Quarters > 3 > balance Sheet > payables
1295000
Quarters > 3 > balance Sheet > short Term Debt
-
Quarters > 3 > balance Sheet > long Term Debt
124000
Quarters > 3 > balance Sheet > total Liabilities
16388000
Quarters > 3 > balance Sheet > equity
28821000
Quarters > 3 > cash Flow > net Income
-23559000
Quarters > 3 > cash Flow > depreciation
9000
Quarters > 3 > cash Flow > change In Working Capital
1848000
Quarters > 3 > cash Flow > cash From Operations
-20677000
Quarters > 3 > cash Flow > capital Expenditures
0
Quarters > 3 > cash Flow > cash From Investing
-
Quarters > 3 > cash Flow > cash From Financing
-625000
Quarters > 3 > cash Flow > net Change In Cash
-21302000
Quarters > 3 > ratios > PE
-41.839302553975166
Quarters > 3 > ratios > PB
2.0514109503487044
Quarters > 3 > ratios > ROE
-81.74247944207349
Quarters > 3 > ratios > ROA
-52.11130527107435
Quarters > 3 > ratios > FCF
-20677000
Quarters > 3 > ratios > Piotroski FScore
1
Quarters > 3 > ratios > fcf Percent
-29.66571018651363
Quarters > 3 > health Score
31
Valuation > metrics > PE
-14.573435955498846
Valuation > metrics > PB
10.985249721500187
Valuation > final Score
20
Valuation > verdict
266.2% Overvalued
Profitability > metrics > ROE
-152.4693650204233
Profitability > metrics > ROA
-56.572058418297054
Profitability > final Score
15
Profitability > verdict
Weak
Risk > metrics > Debt Equity
1.8431117712588192
Risk > metrics > Interest Coverage
-433.10526315789474
Risk > final Score
-1702
Risk > verdict
High
Liquidity > metrics > Current Ratio
10.473304473304474
Liquidity > metrics > Quick Ratio
10.473304473304474
Liquidity > final Score
100
Liquidity > verdict
Great
Prev Valuations > 0
35.14468512898331
Prev Valuations > 1
41.41757047768206
Prev Valuations > 2
80
Prev Profitabilities > 0
15
Prev Profitabilities > 1
15
Prev Profitabilities > 2
0
Prev Risks > 0
-323
Prev Risks > 1
-1580
Prev Risks > 2
-1672
Prev Liquidities > 0
100
Prev Liquidities > 1
100
Prev Liquidities > 2
100
Updated At
2026-01-20T22:37:02.776Z
Spruce Biosciences, Inc. is a biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders. The company develops TA-ERT, a fusion protein comprised of recombinant human alpha-N-acetylglucosaminidase, which is an enzyme replacement therapy for patients with Sanfilippo Syndrome Type B. It also develops Tildacerfont for treating a highly debilitating mental disorder characterized by depressed mood with cognitive-affective and somatic changes, including anhedonia, weight alterations, and altered sleeping patterns. In addition, the company develops SPR202 for the treatment of Congenital Adrenal Hyperplasia (CAH), a chronic and potentially life-threatening rare disease with no cure, and SPR204, a monoclonal antibody antagonist for Post-Bariatric Hypoglycemia. The company has a license agreement with Eli Lilly and Company to research, develop, and commercialize various pharmaceutical compounds. It also has a collaboration and license agreement with Kaken Pharmaceutical Co. Ltd. to develop, manufacture, and commercialize Tildacerfont for the treatment of CAH in Japan. Spruce Biosciences, Inc. was incorporated in 2014 and is headquartered in South San Francisco, California.
Stock Price
$0.00
increase compared to yesterday.
Dividend
Frequency:
Rate:
N/ANext Payout:
N/ASpruce Biosciences (OTC:SPRBD) Shares Up 40.9% – Here’s Why Defense World
Read more →Showing 2 of 10
(Last Updated 2025-09-30)
Health Score
Price to Book Ratio (P/B)
-
Very High
Low ≤ 1
High ≥ 3
Return on Equity (ROE)
-
Very Low
Low ≤ 5%
High ≥ 25%
Return on Assets (ROA)
-
Very Low
Low ≤ 2%
High ≥ 10%
Debt to Equity
-
Very Low
Low ≥ 1
High ≤ 0.3
* Institutions hold a combined 0.00% of the total shares of Spruce Biosciences, Inc.
* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.
No earnings data available.
(Last Updated 2025-09-30)
(Last Updated 2025-09-30)
Revenue
$ 0
Cost Of Revenue
$ 0
Gross Profit
$ 0
Operating Expenses
$ 0
Operating Income
$ 0
Interest Expense
$ 0
Pretax Income
$ 0
Net Income
$ 0
Income Tax Expense
$ 0
EBITDA
$ 0
Total Other Income Expense Net
$ 0
Earnings Per Share
0
Dividends Per Share
0
Shares Outstanding
0
Operating Margin
0%
(Last Updated 2025-09-30)
Cash
$ 0
Short Term Investments
$ 0
Receivables
$ 0
Inventories
$ 0
Total Current Assets
$ 0
Property Plant Equipment
$ 0
Total Assets
$ 0
Payables
$ 0
Short Term Debt
$ 0
Long Term Debt
$ 0
Total Liabilities
$ 0
Equity
$ 0
(Last Updated 2025-09-30)
Net Income
$ 0
Depreciation
$ 0
Change In Working Capital
$ 0
Cash From Operations
$ 0
Capital Expenditures
$ 0
Cash From Investing
$ 0
Cash From Financing
$ 0
Net Change In Cash
$ 0
Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.